SOPHiA GENETICS (SOPH) Earnings Analysis
SOPHiA GENETICS (SOPH) has no confirmed upcoming earnings date. Last quarter (2026-03-03) it missed with EPS -0.28 USD vs -0.2375 USD est (-17.9%). It has beaten estimates in 1/2 recent quarters (50%). Trailing P/E -5.42.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does SOPH next report earnings?
No confirmed upcoming earnings date is currently scheduled for SOPH. This page updates as the calendar is published.
SOPH earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-03 | -0.28 USD | -0.2375 USD | -17.9% | Miss |
| 2025-03-04 | -0.23 USD | -0.23 USD | 0% | Beat |
Beat rate: 1/2 (50%) over reported quarters with consensus data.
SOPH valuation and analyst view
| Trailing P/E | -5.42 |
|---|---|
| Trailing EPS | -1.13774 USD |
| Price / book | 9.97 |
| Dividend yield | 0.00% |
| Market cap | 0.45B |
| Analyst consensus | Buy (6 buy / 1 hold / 0 sell) |
| Avg price target | 12 USD |
Related research pages
Frequently asked questions
When is SOPHiA GENETICS (SOPH)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for SOPH. This page updates as the calendar is published.
Did SOPH beat earnings last quarter?
In its 2026-03-03 report, SOPH posted EPS of -0.28 USD versus a -0.2375 USD estimate — a miss of 17.9%.
What is SOPH's earnings track record?
Over the last 2 reported quarters with consensus data, SOPH beat estimates 1 times (50%).
What is SOPH's current P/E ratio and EPS?
SOPH trades at a trailing P/E of -5.42 on trailing EPS of -1.1377368850752905 USD.
What do analysts rate SOPH?
Analyst consensus is "Buy" across 7 ratings (0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 12 USD.